C4X Stock Overview
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €0.33 |
| 52 Week Low | €0.084 |
| Beta | 1.63 |
| 1 Month Change | 17.83% |
| 3 Month Change | -8.73% |
| 1 Year Change | -58.03% |
| 3 Year Change | -83.57% |
| 5 Year Change | -86.01% |
| Change since IPO | -99.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| C4X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.9% | -3.1% | 1.8% |
| 1Y | -58.0% | -22.4% | 2.2% |
Return vs Industry: C4X underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: C4X underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| C4X volatility | |
|---|---|
| C4X Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C4X has not had significant price volatility in the past 3 months.
Volatility Over Time: C4X's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 39 | Shefali Agarwal | valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.
Valerio Therapeutics Société anonyme Fundamentals Summary
| C4X fundamental statistics | |
|---|---|
| Market cap | €17.87m |
| Earnings (TTM) | -€19.73m |
| Revenue (TTM) | €1.44m |
12.4x
P/S Ratio-0.9x
P/E RatioIs C4X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C4X income statement (TTM) | |
|---|---|
| Revenue | €1.44m |
| Cost of Revenue | €491.00k |
| Gross Profit | €952.00k |
| Other Expenses | €20.69m |
| Earnings | -€19.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 65.97% |
| Net Profit Margin | -1,367.64% |
| Debt/Equity Ratio | 55.3% |
How did C4X perform over the long term?
See historical performance and comparison